New York, June 5, 2026, 06:06 EDT
- OraSure was last seen at $4.17, up 5.6% from its previous close, ahead of the regular Nasdaq open.
- Shareholders gave the nod to a phased board declassification and signed off on expanding the stock-award pool.
- OraSure’s 2026 product milestones stay in focus after the board vote and a spring deal with Altai Capital.
Shares of OraSure Technologies traded at $4.17, up 22 cents on the day. The diagnostics firm said it had support from shareholders for a board overhaul. OraSure, which trades on Nasdaq, had a market cap around $291 million.
Timing is key here. Nasdaq’s standard trading day in New York wasn’t underway yet; the exchange lists regular hours as 9:30 a.m. to 4 p.m. Eastern, and premarket runs from 4 a.m. up until 9:30 a.m. June 5 isn’t shown as a 2026 market holiday for Nasdaq, with Juneteenth on June 19 as the next scheduled market closure.
OraSure said in a filing June 3 that its shareholders voted to end the company’s classified board over the next three years, starting with the 2027 meeting. Directors will then face annual elections instead of staggered terms. Shareholders also okayed an extra 5 million shares for OraSure’s stock award plan, elected John D. Bertrand, Steven K. Boyd, and Robert W. McMahon as Class II directors, and supported executive pay in a vote of 45.2 million to 6.2 million.
Bertrand’s election gets extra attention after OraSure picked him in April as part of a cooperation deal with Altai Capital. Altai dropped its director nominees and agreed to keep in touch with the board and management. Back then, board chair Jack Kenny called the plan to declassify the board “strong governance.” Altai’s Rishi Bajaj said he was “pleased with the outcome.” OraSure Technologies
OraSure’s latest governance vote comes as the company is still working to get growth going after shrinking back from its COVID-fueled peak. First-quarter revenue slipped 7% to $27.9 million. CEO Carrie Eglinton Manner called the result “above the midpoint” of guidance. Gross margin edged up to 42.3% from 41.1%. Operating loss widened to $23.3 million compared with $17.8 million a year ago. OraSure’s revenue outlook for the second quarter is $27 million to $30 million. GlobeNewswire
The activist push is still in the background. Back in March, Reuters said Altai, which had around 5% of OraSure, called for the company to consider selling itself, arguing a deal could fetch between $4.54 and $6.60 per share. Bajaj also said OraSure would get “significantly more in a sale” than it could on its own. That same Reuters piece described point-of-care diagnostics as a fragmented field, with bigger companies like Abbott, Danaher and Thermo Fisher controlling most of the market. Reuters
The stock’s got both a governance angle and an execution challenge. Board moves could calm a few investors, but don’t address slower revenue, operating losses, or getting new products to actually bring in sales.
The risk is clear. If product approvals get delayed, launches miss expectations, or cost cuts don’t speed up margins, shares could lose steam. Another round of sale talk could shift things, mainly if the market begins to price OraSure more on buyout hopes than actual revenue each quarter.
